Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT 19 gemcitabine switch maintenance in malignant pleural mesothelioma
NL-OMON47831Phase 2Completed
- Sponsor
- NVALT
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pleural mesothelioma comparing Gemcitabine maintenance with Best supportive care (2 arms). Primary endpoint: Progression-free survival. Started Mar 2014; status: completed.
02
Drugs
gemcitabine
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON47831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47831.